Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG0001 in Peripheral Ischemic Ulcers
NCT04267640Phase 2Unknown
- Sponsor
- AnGes, Inc.
- Start
- Jan 2020
- Primary completion
- Jul 2022
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 2 trial of beperminogene perplasmid in peripheral artery disease (PAD), chronic limb-threatening ischemia (CLTI), sponsored by AnGes, Inc.. Status: unknown.
02
Drugs
beperminogene perplasmid
03
Conditions
peripheral artery disease (PAD)chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on NCT04267640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267640.